NASDAQ:CNSP CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis → Collect 10%+ Dividends from AI's Explosive Growth? (From The Oxford Club) (Ad) Free CNSP Stock Alerts $2.79 -0.83 (-22.93%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$2.79▼$8.2850-Day Range$2.79▼$12.1752-Week Range$2.79▼$137.50Volume9.93 million shsAverage Volume84,573 shsMarket Capitalization$669,600.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get CNS Pharmaceuticals alerts: Email Address Ad The Oxford ClubCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having to buy a single stock?Click here now to claim your FREE copy of Marc's AI playbook. About CNS Pharmaceuticals Stock (NASDAQ:CNSP)CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Read More CNSP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CNSP Stock News HeadlinesJune 12 at 1:55 AM | americanbankingnews.comAnalyzing Amarin (NASDAQ:AMRN) and CNS Pharmaceuticals (NASDAQ:CNSP)May 22, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at 2024 Healthcare Company ShowcaseMay 16, 2024 | investorplace.comCNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q1 2024May 16, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2024 Financial ResultsApril 25, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) CEO to Present at LSX World Congress 2024April 4, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Releases FY 2023 Financial Report, Corporate UpdateApril 3, 2024 | benzinga.comCNS Pharma Stock (NASDAQ:CNSP), Earnings Estimates, EPS, and RevenueApril 2, 2024 | investorplace.comCNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023March 20, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Welcomes Proven Commercialization Leader to BoardFebruary 9, 2024 | investing.comCns Pharmaceuticals Inc (CNSP)February 3, 2024 | msn.comCNS Pharmaceuticals Launches Public Offering for Trial FundingJanuary 30, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Releases Info on $4M Public Offering PricingJanuary 29, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $4.0 Million Public OfferingJanuary 29, 2024 | finance.yahoo.comCNS Pharmaceuticals Announces Pricing of $4.0 Million Public OfferingJanuary 19, 2024 | theglobeandmail.comCNS Pharmaceuticals (NASDAQ: CNSP) Names Seasoned Biotech Leader to Board of DirectorsJanuary 18, 2024 | finanznachrichten.deCNS Pharmaceuticals, Inc.: Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of DirectorsJanuary 18, 2024 | finance.yahoo.comBiotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of DirectorsJanuary 17, 2024 | finance.yahoo.comCNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM)January 6, 2024 | seekingalpha.comCNSP CNS Pharmaceuticals, Inc.December 18, 2023 | finance.yahoo.comCNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of BerubicinDecember 14, 2023 | morningstar.comCNS Pharmaceuticals Inc Ordinary SharesDecember 8, 2023 | msn.comCNS Pharmaceuticals files to sell 3.81M shares of common stockDecember 6, 2023 | finance.yahoo.comHow CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No CureNovember 22, 2023 | finance.yahoo.comCNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of EfficacyNovember 21, 2023 | msn.comCNS Pharmaceuticals files to sell 3.76M shares of common stock for holdersSee More Headlines Receive CNSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/15/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CNSP CUSIPN/A CIK1729427 Webwww.cnspharma.com Phone800-946-9185FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($174.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-603.40% Return on Assets-575.33% Debt Debt-to-Equity RatioN/A Current Ratio0.26 Quick Ratio0.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($35.66) per share Price / Book-0.08Miscellaneous Outstanding Shares240,000Free Float215,000Market Cap$669,600.00 OptionableNot Optionable Beta2.75 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. John Michael Climaco Esq. (Age 55)J.D., CEO, President & Director Comp: $525kMr. Christopher S. Downs CPA (Age 45)CTP, FP&A, Chief Financial Officer Comp: $382.16kDr. Sandra L. Silberman M.D. (Age 68)Ph.D., Chief Medical Officer Comp: $261.2kDr. Waldemar Priebe Ph.D.FounderDr. Donald H. Picker Ph.D. (Age 78)Chief Science Officer Key CompetitorsAvenue TherapeuticsNASDAQ:ATXIAridis PharmaceuticalsNASDAQ:ARDSSonoma PharmaceuticalsNASDAQ:SNOAAyala PharmaceuticalsNASDAQ:ADXSNovaBay PharmaceuticalsNYSE:NBYView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 81,094 shares on 5/20/2024Ownership: 0.795%Christopher DownsBought 540 shares on 8/22/2023Total: $34,290.00 ($63.50/share)John M ClimacoBought 55 shares on 8/16/2023Total: $4,950.00 ($90.00/share)View All Insider TransactionsView All Institutional Transactions CNSP Stock Analysis - Frequently Asked Questions How have CNSP shares performed in 2024? CNS Pharmaceuticals' stock was trading at $63.50 at the beginning of the year. Since then, CNSP stock has decreased by 95.6% and is now trading at $2.79. View the best growth stocks for 2024 here. Are investors shorting CNS Pharmaceuticals? CNS Pharmaceuticals saw a decrease in short interest in May. As of May 31st, there was short interest totaling 4,000 shares, a decrease of 93.6% from the May 15th total of 62,500 shares. Based on an average daily trading volume, of 25,700 shares, the short-interest ratio is presently 0.2 days. Currently, 1.8% of the shares of the stock are short sold. View CNS Pharmaceuticals' Short Interest. When is CNS Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our CNSP earnings forecast. How were CNS Pharmaceuticals' earnings last quarter? CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) issued its quarterly earnings data on Wednesday, May, 15th. The company reported ($20.50) earnings per share for the quarter. When did CNS Pharmaceuticals' stock split? Shares of CNS Pharmaceuticals reverse split before market open on Wednesday, June 5th 2024. The 1-50 reverse split was announced on Wednesday, June 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of CNS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other CNS Pharmaceuticals investors own include Fulcrum Therapeutics (FULC), Advanced Micro Devices (AMD), Heat Biologics (HTBX), Roku (ROKU), Aldeyra Therapeutics (ALDX), Salesforce (CRM), Gilead Sciences (GILD), Inseego (INSG), Nokia Oyj (NOK) and Block (SQ). When did CNS Pharmaceuticals IPO? CNS Pharmaceuticals (CNSP) raised $9 million in an initial public offering on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO. Who are CNS Pharmaceuticals' major shareholders? CNS Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.80%). Insiders that own company stock include Christopher Downs, Jerzy Gumulka, John M Climaco and Waldemar Priebe. View institutional ownership trends. How do I buy shares of CNS Pharmaceuticals? Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CNSP) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWho are Nvidia’s Silent Partners?Nvidia recently became just the third $2 trillion company. But Nvidia can’t do everything by itself.Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.